Literature DB >> 2105167

Reactivity of lymphocytes to a progesterone receptor-specific monoclonal antibody.

J Szekeres-Bartho1, G Szekeres, P Debre, B Autran, G Chaouat.   

Abstract

In this study we present evidence for reactivity of pregnancy lymphocytes, but not nonpregnancy lymphocytes, with the progesterone receptor-specific monoclonal antibody mPRI. Using an avidin-biotin peroxidase detection system, we found a nuclear staining in 14.6 +/- 3.7% (mean +/- SEM, N = 27) of pregnancy lymphocytes, while only 0.47 +/- 0.33% (mean +/- SEM, N = 15) of nonpregnancy lymphocytes reacted with the antibody. To characterize the receptor-bearing subset, CD8+ and CD4+ cells were depleted by complement-dependent lysis. Depletion of CD8+ cells was accompanied by 62 +/- 18% loss of progesterone receptor-bearing cells, while depletion of CD4+ cells resulted in a twofold increase in the number of positively staining lymphocytes. In nonpregnancy lymphocytes a 3-day PHA treatment, as well as allogeneic stimulation, resulted in a significant increase in the number of receptor-containing cells. These results suggest that pregnancy, but not nonpregnancy, lymphocytes contain progesterone binding structures, and that these are inducible by mitogenic or alloantigenic stimuli.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2105167     DOI: 10.1016/0008-8749(90)90083-4

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  22 in total

1.  Regulation of leucocyte subpopulations in the sheep endometrium by progesterone.

Authors:  S L Gottshall; P J Hansen
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

2.  A corpus luteum is not a prerequisite for the expression of progesterone induced blocking factor by T-lymphocytes a week after implantation.

Authors:  J H Check; J Szekeres-Bartho; P Nazari; Y Katz; M L Check
Journal:  J Assist Reprod Genet       Date:  2001-11       Impact factor: 3.412

3.  Endometrial leucocytes: expression of steroid hormone receptors.

Authors:  J A Stewart; J N Bulmer; A P Murdoch
Journal:  J Clin Pathol       Date:  1998-02       Impact factor: 3.411

Review 4.  The Role of Progesterone in Feto-Maternal Immunological Cross Talk.

Authors:  Julia Szekeres-Bartho
Journal:  Med Princ Pract       Date:  2018-06-27       Impact factor: 1.927

Review 5.  Role of nuclear progesterone receptor isoforms in uterine pathophysiology.

Authors:  Bansari Patel; Sonia Elguero; Suruchi Thakore; Wissam Dahoud; Mohamed Bedaiwy; Sam Mesiano
Journal:  Hum Reprod Update       Date:  2014-11-18       Impact factor: 15.610

Review 6.  Membrane progesterone receptor expression in mammalian tissues: a review of regulation and physiological implications.

Authors:  Gwen E Dressing; Jodi E Goldberg; Nathan J Charles; Kathryn L Schwertfeger; Carol A Lange
Journal:  Steroids       Date:  2010-09-24       Impact factor: 2.668

Review 7.  New approaches to making the microenvironment of the female reproductive tract hostile to HIV.

Authors:  John V Fahey; Jack E Bodwell; Danica K Hickey; Mimi Ghosh; Maria N Muia; Charles R Wira
Journal:  Am J Reprod Immunol       Date:  2011-01-12       Impact factor: 3.886

Review 8.  Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.

Authors:  Zdenek Hel; Elizabeth Stringer; Jiri Mestecky
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

Review 9.  Characteristics of membrane progestin receptor alpha (mPRalpha) and progesterone membrane receptor component 1 (PGMRC1) and their roles in mediating rapid progestin actions.

Authors:  Peter Thomas
Journal:  Front Neuroendocrinol       Date:  2008-02-01       Impact factor: 8.606

10.  Progesterone modulates the T-cell response via glucocorticoid receptor-dependent pathways.

Authors:  Alexandra Maximiliane Hierweger; Jan Broder Engler; Manuel A Friese; Holger M Reichardt; John Lydon; Francesco DeMayo; Hans-Willi Mittrücker; Petra Clara Arck
Journal:  Am J Reprod Immunol       Date:  2019-01-28       Impact factor: 3.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.